The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 25, 2022
Filed:
Aug. 31, 2017
Applicant:
Amgen Inc., Thousand Oaks, CA (US);
Inventors:
Andrew A. Welcher, Ventura, CA (US);
Michael J. Boedigheimer, Newbury Park, CA (US);
James B. Chung, Thousand Oaks, CA (US);
Assignee:
AMGEN INC., Thousand Oaks, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01); A61K 31/42 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61K 31/5377 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61K 31/365 (2006.01);
U.S. Cl.
CPC ...
C07K 16/249 (2013.01); A61K 31/365 (2013.01); A61K 31/42 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 31/573 (2013.01); A61K 39/0005 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C12Q 1/6883 (2013.01); G01N 33/68 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/52 (2013.01);
Abstract
The invention encompasses methods of treatment of interferon gamma (IFN-γ)-mediated diseases using IFN-γ inhibitors, such as anti-huIFN-γ antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-γ inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-γ antibody.